2024-01-12 08:00:00
Chinese green light for Biogen
The This group (Lecanemab) Biogen has just been authorized by Chinese health authorities for the treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease. 17 million people would be eligible for this treatment on Chinese territory. China is the third country to approve the drug, following the United States and Japan. In Europe, Leqembi is still in the evaluation phase with the authorities.
Good results on diabetes for Novo Nordisk
Novo Nordisk presented the phase III results of its trial evaluatingIcoSema, a combination of icodec insulin and semaglutide, once a week, in people with type 2 diabetes not adequately controlled by insulin treatment. After one year, the combination demonstrated non-inferiority in reducing glycolated hemoglobin levels compared to treatment with standard insulins.
I will tell you
source
Priority review for Pfizer and Genmab
FDA has agreed to grant priority review to the world’s No. 1 Supplemental Biological License Application (sBLA) Pfizer and its partner, the Danish biotech Genmab. The request concerns the Tivdak (tisotumab vedotin) for the treatment of recurrent or metastatic cervical cancer that has not responded to first-line treatment. The deadline for the final decision is May 9, 2024.
Selected for you
1705081639
#Biogen #Novo #Nordisk #Pfizer #Genmab
